drugset / Trial / NCT07349160
Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
Phase 0
Recruiting
36 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Leman Biotech Co., Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
A Study of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) Therapy for Patients With Advanced Solid Tumors
Timeline
- Start
- 2026-01-10
- Primary completion
- 2027-03-15
- Completion
- 2028-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metabolically Armed TIL cells | Cell therapy | — | Intravenous |